Foreign securities can be subject to greater risks than U.S. investments, including currency fluctuations, less liquid trading markets, greater price volatility, political and economic instability, less publicly available information, and changes in tax or currency laws or monetary policy. These risks are likely to be greater for emerging markets than in developed markets.
Large-Capitalization Companies Risk: Large-capitalization companies may be less able than smaller capitalization companies to adapt to changing market conditions. Large-capitalization companies may be more mature and subject to more limited growth potential compared with smaller capitalization companies. During different market cycles, the performance of large-capitalization companies has trailed the overall performance of the broader securities markets.
New Fund Risk The Fund is a new fund. As a new fund, there can be no assurance that it will grow to or maintain an economically viable size, in which case it could ultimately liquidate.
Small and mid-cap stocks are often more volatile than large-cap stocks. Smaller companies generally face higher risks due to their limited product lines, markets and financial markets.
ESG Investing Style Risk Impact investing and/or Environmental, Social and Governance (ESG) managers may take into consideration factors beyond traditional financial information to select securities, which could result in relative investment performance deviating from other strategies or broad market benchmarks, depending on whether such sectors or investments are in or out of favor in the market. Further, ESG strategies may rely on certain values based criteria to eliminate exposures found in similar strategies or broad market benchmarks, which could also result in relative investment performance deviating. There is no assurance that employing ESG strategies will result in more favorable investment performance.
The IQ CANDRIAM Healthy Hearts Index seeks to provide investors with exposure to select companies that are involved in the diagnosis and/or treatment of heart disease, or that provide goods or services that allow people to adopt or maintain a healthy lifestyle.
New York Life Investment Management LLC (NYLIM) and IndexIQ Advisors LLC (IndexIQ) are donors to and supporters of American Heart Association’s Social Impact Fund and are making a substantial contribution to the Social Impact Fund.
Shares of the Fund are not sponsored, endorsed or promoted by American Heart Association, Inc. (“AHA”). The Fund’s sponsor, IndexIQ, and its affiliates are donors to and supporters of AHA’s Social Impact Fund and are making a substantial contribution to the Social Impact Fund in connection with AHA’s agreement to license use of its name and trademarks to IndexIQ and its affiliates. AHA makes no representation or warranty, express or implied, to prospective or actual investors in the Fund or to any member of the public regarding the advisability of investing in any financial product, including one seeking to track the Underlying Index, the ability of the Fund to track the performance of the Underlying Index, the ability of the Underlying Index to meet or exceed stock market performance, the suitability of the Fund or the ability of the Underlying Index or Fund to achieve its investment goals. AHA has no obligation or liability in connection with the administration, marketing or trading of shares of the Fund. AHA is not an investment adviser or a fund distributor or service provider. Inclusion of a security within the Underlying Index is not a recommendation by AHA to buy, sell or hold such security, nor is it considered to be investment advice or a guarantee that the investment goals of the Underlying Index will be achieved. AHA does not guarantee the accuracy and/or the completeness of the Underlying Index or any data included therein.
1. American Heart Association. “Heart Disease and Stroke Statistics—2021 Update: A Report from the American Heart Association.” Published Jan. 27, 2021
3. Centers for Disease Control and Prevention. “Heart Disease Facts.” Accessed 4 Oct. 2021. https://www.cdc.gov/heartdisease/facts.htm
4. Fortune Business Insights, Cardiovascular Drugs Market Size, Share & Industry Analysis, By Drug Type, By Disease Indication, By Distribution Channel and Regional Forecast, 2019-2026. As of Nov. 2019.
5. Nielsen Retail Measurement Services. “How America Will Eat.” Data from 52-week period ended Oct. 26, 2019 vs. year ago.
6. Allied Market Research, Fitness Equipment Market by Type (Cardiovascular Training Equipment, Strength Training Equipment and Other Equipment) and End User (Home Consumer, Health Club/Gym and Other Commercial User): Global OpportunityAnalysis and Industry Forecast, 2020-2027. As of Mar. 2020.